INO 8000

Drug Profile

INO 8000

Alternative Names: Hepatitis C vaccine - Inovio/VGX; INO-8000; VGX-6150

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Mayo Clinic
  • Class DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatitis C

Most Recent Events

  • 01 Jul 2017 GeneOne and Inovio Pharmaceuticals completes a phase I trial for Hepatitis C in South Korea (NCT02027116)
  • 01 Jul 2016 Inovio Pharmaceuticals and National Cancer Institute initiate enrolment in a phase I trial for Hepatitis C in USA (NCT02772003)
  • 01 Jun 2016 Phase-I clinical trials in Hepatitis C in USA (IM) (NCT02822079)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top